Cargando…
Evaluation of Efficacy and Safety of Fixed Dose Lovastatin and Niacin(ER) Combination in Asian Indian Dyslipidemic Patients: A Multicentric Study
Asian Indian dyslipidemia is characterized by: borderline high low-density lipoprotein (LDL) cholesterol and apolipoprotein (apo) B; high triglycerides, low high-density lipoprotein (HDL) cholesterol and apoA1; and high lipoprotein(a) (lp[a]). We performed a controlled multicentric trial in India to...
Autores principales: | Sharma, Manoj, Sharma, Deepika R, Singh, Vikram, Panwar, RB, Hira, HS, Mohan, Bishav, Kumar, Naveen, Sharma, SK, Gupta, Rajeev |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1993969/ https://www.ncbi.nlm.nih.gov/pubmed/17319473 |
Ejemplares similares
-
Simultaneous determination of lovastatin and niacin in tablet by first and third derivative spectrophotometry and H-point standard addition methods
por: Kazemipour, M., et al.
Publicado: (2012) -
Cost-Effectiveness Analysis of Simvastatin and Lovastatin/Extended-Release Niacin to Achieve LDL and HDL Goal Using NHANES Data
por: Armstrong, Edward P., et al.
Publicado: (2004) -
HDL-C Response Variability to Niacin ER in US Adults
por: Christian, Jennifer B., et al.
Publicado: (2013) -
Improved bioavailability through floating microspheres of lovastatin
por: Kumar, S., et al.
Publicado: (2011) -
Targeting mulitple dyslipidemias with fixed combinations – focus on extended release niacin and simvastatin
por: Pandian, Anbu, et al.
Publicado: (2008)